SCHEMBL1779425

SCHEMBL1779425

CCOC(=O)n1nc(NC(=O)c2ccccc2NC(=O)c2ccco2)c2cc(C(=O)O)sc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 5/20 0.46
ALDH1A1 P00352 12/20 0.45
TSHR P16473 6/20 0.45
HTT P42858 2/20 0.45
KDM4E B2RXH2 14/20 0.45
HPGD P15428 7/20 0.45
MAPT P10636 4/20 0.45
NPSR1 Q6W5P4 4/20 0.45
HSD17B10 Q99714 6/20 0.44
ATM Q13315 2/20 0.44
KMT2A Q03164 3/20 0.44
POLB P06746 2/20 0.44
MEN1 O00255 2/20 0.44
ESR1 P03372 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.43
TDP1 Q9NUW8 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
TP53 P04637 2/20 0.43
GAA P10253 2/20 0.43
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL739402 0.92 KDM4E (0.46) MAPK1ALDH1A1TSHRHTTKDM4E
SCHEMBL1780033 0.91 KDM4E (0.44) MAPK1ALDH1A1TSHRHTTKDM4E
SCHEMBL1778509 0.89 RXFP1 (0.41) MAPK1ALDH1A1TSHRHTTKDM4E
SCHEMBL4592688 0.88 KDM4E (0.44) MAPK1ALDH1A1TSHRHTTKDM4E
SCHEMBL1778750 0.86 BTK (0.45) ALDH1A1KDM4EHPGDMAPTHSD17B10
SCHEMBL1778410 0.86 ALDH1A1 (0.40) MAPK1ALDH1A1TSHRHTTKDM4E
SCHEMBL1779174 0.85 RAB9A (0.39) ALDH1A1TSHRKDM4EMAPTNPSR1
SCHEMBL1778607 0.85 ALDH1A1 (0.38) ALDH1A1TSHRKDM4EHPGDMAPT
SCHEMBL1779165 0.84 KDM4E (0.38) ALDH1A1TSHRKDM4EHPGDMAPT
SCHEMBL1779798 0.83 KDR (0.40) ALDH1A1TSHRHTTKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP disclosed
US-7943654-B2 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-17 US disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 MAPK1 66/4885ALDH1A1 3557/4885TSHR 560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.